

Published in final edited form as:

Bioorg Med Chem Lett. 2013 May 15; 23(10): 2860–2862. doi:10.1016/j.bmcl.2013.03.111.

Kappa-Opioid Receptor-Selective Dicarboxylic Ester-Derived Salvinorin A Ligands

Prabhakar R. Polepally^a, Kate White^b, Eyal Vardy^b, Bryan L. Roth^b, Daneel Ferreira^a, and Jordan K. Zjawiony^a

^aDepartment of Pharmacognosy, and Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677-1848, USA

^bDepartment of Pharmacology, School of Medicine and Division of Chemical Biology and Medicinal Chemistry, School of Pharmacy, NIMH Psychoactive Drug Screening Program, University of North Carolina, Chapel Hill, NC 27599, USA

Abstract

Salvinorin A, the active ingredient of the hallucinogenic plant *Salvia divinorum* is the most potent known naturally occurring hallucinogen and is a selective κ -opioid receptor agonist. To better understand the ligand-receptor interactions, a series of dicarboxylic ester-type of salvinorin A derivatives were synthesized and evaluated for their binding affinity at κ , δ , and μ -opioid receptors. Most of the analogues show high affinity to the κ -opioid receptor. Methyl malonyl derivative **4** shows the highest binding affinity ($K_i = 2$ nM), analogues **5**, **7**, and **14** exhibit significant affinity for the κ -receptor ($K_i = 21$, 36 and 39 nM).

Keywords

Salvia divinorum; Salvinorin A and B; Dicarboxylic ester-type ligands; Kappa opioid receptor agonists

The neoclerodane diterpenoid salvinorin A (**1**) isolated from the leaves of hallucinogenic sage *Salvia divinorum*, is a potent and selective κ -opioid receptor (KOR) agonist.^{1, 2} Since its discovery, a large number of analogues have been prepared by semi-synthesis to probe the pharmacophore and mode of binding.³ Some of these analogues present interesting pharmacological profiles from full KOR agonist to partial δ -opioid receptor (DOR) or μ -opioid receptor (MOR) agonist and antagonists. The current objective is to utilize the knowledge about salvinorin A-KOR interactions to rationally design salvinorin A derivatives with different pharmacological profiles and therapeutic potential. In the course of our work on the molecular mechanism of interaction of salvinorin A with KOR, we reported irreversible binding of 22-thiocyanatosalvinorin A (**2**) (Fig. 1) with the sulfhydryl group of Cys-315 at the κ -opioid receptor.^{4, 5} Our previous work on the KOR model and analysis of the mode of binding of **2** suggest that Cys-315 may be a good anchoring amino acid at the binding site in KOR.^{4, 6} The presence of ester substituents at C-22 may enhance

© 2013 Elsevier Ltd. All rights reserved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary data

Supplementary data associated with this article can be found, in the online version.

electrophilicity of this center and thereby leads to stronger binding with the thiol group of Cys-315 of KOR.

Herein, we report the synthesis of series of new dicarboxylic ester salvinorin A derivatives and their binding affinity to κ , δ and μ -opioid receptors.

Salvinorin A (**1**) was isolated from dried leaves of *Salvia divinorum* and purified as previously reported.⁷ It was hydrolyzed to salvinorin B (**3**), which served as the starting material for the preparation of the C(2)-modified dicarboxylic ester analogue library **4-16** (Schemes 1 and 2). Compounds **4-10**, **14**, and **15** were prepared⁸ in yields of 57-69% by reacting **3** with the corresponding acid halides in the presence of Et₃N in DCM (Schemes 1 and 2). Analogues **11-13** and **16** were synthesized⁹ in yields of 40-51% via the reaction of **3** with appropriate anhydrides using DBU (1, 8-diazabicyclo [5.4.0] undec-7-ene) as base (Schemes 1 and 2). The physical data (¹H NMR, ¹³C NMR and HR-ESIMS) were consistent with the proposed structures.

The κ , δ and μ -opioid receptor binding affinities of synthesized compounds **4-16** were evaluated at the NIMH-sponsored Psychoactive Drug Screening Program (PDSP), University of North Carolina at Chapel Hill using radioligand binding assays conducted as previously described,^{1, 5} and the data are collated in Tables 1 and 2. For comparison purposes, opioid binding affinity data for compounds **1-3** and positive controls for MOR and DOR are included in Table 1. Most of the dicarboxylic ester derivatives show appreciable binding affinity to KOR, and no affinity to MOR and DOR. The methyl malonyl derivative **4** had higher affinity than **1** at KOR ($K_i = 2.0$ vs 6.2 nM) (Table 1). The ethyl malonyl and methyl succinyl ligands **5** and **7**, also have significant affinities to KOR, these being respectively 3- and 6-fold reduced compared to **1** ($K_i = 21.0$ and 36, respectively, vs 6.2 nM). The KOR affinities of analogues **6**, **8**, and **9** were decreased 24-, 70-, and 49-fold as compared to **1** ($K_i = 148$, 437 and 302, respectively, vs 6.2 nM). Similarly, compounds **10**, **12**, and **15** show reduced affinity ($K_i = 575$, 263, and 427 nM respectively) at KOR. Interestingly, the methyl fumaryl ligand **14** had a 6-fold reduced but still considerable affinity for the κ -opioid receptor compared to **1** ($K_i = 39$ vs 6.2 nM). Analogues **11** and **16** exhibited less affinity for the κ -receptor ($K_i = 4070$ and 2291 nM, respectively), and derivative **13** has no affinity for any of the opioid receptors.

To characterize the relative efficacy of these dicarboxylic ester ligands, compounds **4**, **5**, **7**, and **14** together with salvinorin A (**1**) were selected for a functional assay. Table 2 shows the EC₅₀ values of these ligands in stimulating G α_i signaling mediated by the κ -opioid receptor.

In summary, a series of new dicarboxylic ester-type analogues of salvinorin A were synthesized in an effort to explore the effects of C-2 substitution towards selectivity at κ , δ , and μ -opioid receptors. Most of the analogues showed high binding affinity to the κ -opioid receptor with little affinity for δ - and μ -opioid receptors. Compound **4** possessing a C-2 methyl malonyl group exhibited increased selectivity for KOR compared to the parent salvinorin A (**1**).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the NIH Grant R01 DA017204 and the NIMH Psychoactive Drug Screening Program (PDSP), University of North Carolina at Chapel Hill, NC 27599. We thank Mr. Daniel J. Siebert from the *Salvia*

divinorum Research and Information Center for supplying the plant material, and Dr. Bin Wang for the assistance with HRESIMS.

References and notes

1. Ortega A, Blount JF, Manchand PS. *J. Chem. Soc., Perkin Trans.1.* 1982:2505–2508.
2. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB. *Proc. Natl. Acad. Sci. U.S.A.* 2002; 99:11934–11939. [PubMed: 12192085]
3. (a) Beguin C, Potuzak J, Xu W, Liu - Chen LY, Streicher JM, Groer CE, Bohn LM, Carlezon WA Jr. *Cohen BM. Bioorg. Med. Chem. Lett.* 2012; 22:1023–1026. [PubMed: 22204910] (b) Lovell KM, Vasiljevik T, Araya JJ, Lozama A, Prevatt-Smith KM, Day VW, Dersch CM, Rothman RB, Butelman ER, Kreek MJ, Prisinzano TE. *Bioorg. Med. Chem.* 2012; 20:3100–3110. [PubMed: 22464684] (c) Cunningham CW, Rothman RB, Prisinzano TE. *Pharmacol. Rev.* 2011; 63:316–347. [PubMed: 21444610] (d) Lozama A, Cunningham CW, Caspers MJ, Douglas JT, Dersch CM, Rothman RB, Prisinzano TE. *J. Nat. Prod.* 2011; 74:718–726. [PubMed: 21338114] (e) Tidgewell K, Harding WW, Lozama A, Cobb H, Shah K, Kannan P, Dersch CM, Parrish D, Deschamps JR, Rothman RB, Prisinzano TE. *J. Nat. Prod.* 2006; 69:914–918. [PubMed: 16792410] (f) Bikbulatov RV, Yan F, Roth BL, Zjawiony JK. *Bioorg. Med. Chem. Lett.* 2007; 17:2229–2232. [PubMed: 17303418] (g) Lee DY, He M, Liu-Chen L-Y, Wang Y, Li J-G, Xu W, Ma Z, Carlezon WA Jr. *Cohen B. Bioorg. Med. Chem. Lett.* 2006; 16:5498–5502. [PubMed: 16945525] (h) Stewart DJ, Fahmy H, Roth BL, Yan F, Zjawiony JK. *Arzneimittelforschung.* 2006; 56:269–275. [PubMed: 16724512] (i) Beguin C, Richards MR, Li JG, Wang Y, Xu W, Liu - Chen LY, Carlezon WA Jr. *Cohen BM. Bioorg. Med. Chem. Lett.* 2006; 16:4679–4685. [PubMed: 16777411] (j) Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, Prisinzano TE. *J. Med. Chem.* 2005; 48:4765–4771. [PubMed: 16033256] (k) Lee DY, Yang L, Xu W, Deng G, Guo L, Liu-Chen LY. *Bioorg. Med. Chem. Lett.* 2010; 20:5749–5752. [PubMed: 20801035]
4. Yan F, Bikbulatov RV, Mocanu V, Dicheva N, Parker CE, Westel WC, Mosier PD, Westkaemper RB, Allen JA, Zjawiony JK, Roth BL. *Biochem.* 2009; 48:6898–6908. [PubMed: 19555087]
5. Wu H, Wacker D, Mileni M, Katritch V, Han GW, Vardy E, Liu W, Thompson AA, Huang XP, Carroll FI, Mascarella SW, Westkaemper RB, Mosier PD, Roth BL, Cherezov V, Stevens RC. *Nature.* 2012; 485:327–332. [PubMed: 22437504]
6. Yan F, Mosier PD, Westkaemper RB, Stewart J, Zjawiony JK, Vortherms TA, Sheffler DJ, Roth BL. *Biochem.* 2005; 44:8643–8651. [PubMed: 15952771]
7. Kutrzeba LM, Karamayan VT, Speth RC, Williamson JS, Zjawiony JK. *Pharm. Biol.* 2009; 47:1078–1084.
8. Procedure for the synthesis of analogues **4-10**, **14** and **15**: Compound **3** (15 mg, 0.05 mmol) and a catalytic amount of triethylamine were dissolved in DCM (3 mL). An appropriate acid chloride (0.125 mmol) was added, and the reaction mixture was stirred for 2-3 h at rt. After TLC indicated completion of the reaction, the mixture was quenched with water and the organic layer separated. The organic phase was washed with dilute aqueous HCl (0.01 mol/L, 2 mL) followed by saturated NaHCO₃ (2 mL). The organic layer was dried over anhydrous Na₂SO₄, evaporated, and the residue was purified by column chromatography (SiO₂; eluent: *n*-hexane / EtOAc) to obtain the target product. In some cases purification was done by preparative HPLC (C₁₈ column, MeCN-water).
9. Method for the synthesis of derivatives **11-13** and **16**: To a solution of compound **3** (15 mg, 0.05 mmol) in DCM (3 mL), a catalytic amount of DBU and an appropriate acid anhydride (0.15 mmol) were added. The mixture was stirred at room temperature for 6-8 h. After TLC indicated completion of the reaction, the mixture was concentrated under reduced pressure and the residue was purified by column chromatography (SiO₂; eluent: *n*-hexane / EtOAc) and HPLC (C₁₈ column, MeCN-water) to yield the target product.






Figure 1.
The structures of salvinorin A, 22-thiocyanatosalvinorin A, and salvinorin B.

**Scheme 1.**

Synthesis of dicarboxylic ester-type salvinorin A analogues **4-12** Reagents and conditions: (a) appropriate acid chloride, Et₃N, dry DCM, N₂ r.t, 2-3 h, or appropriate acid anhydride, DBU, dry DCM, N₂, r.t, 6-8 h.

**Scheme 2.**

Synthetic route for the designed ligands **13-16**. Reagents and conditions: (a) appropriate acid chloride, Et₃N, dry DCM, N₂, r.t., 3 h, or appropriate acid anhydride, DBU, dry DCM, N₂, r.t., 6-8 h.

Table 1

Binding affinities of C(2)-dicarboxylic ester-derived salvinorin A analogues (**4-16**) at MOR, DOR, and KOR

Compound	Affinities, ^b $K_i \pm$ SD [nM]			Selectivity		
	MOR ^c	DOR ^d	KOR ^e	MOR/KOR	DOR/KOR	DOR/KOR
1	>10000	>10000	6.2±2.2			
Naltrindole	ND	0.9±0.3	ND			
DAMGO	0.9±0.2	ND	ND			
2 ^a	>10000	>10000	0.6±0.2			
3	>10000	>10000	>10000			
4	>10000	4320±680	2.0±0.3	>5000		2160
5	>10000	>10000	21.0±5.6	>476		>476
6	>10000	>10000	148±32	>67		>67
7	>10000	>10000	36±8	>277		>277
8	>10000	>10000	437±129	>23		>23
9	5012±1400	>10000	302±94	16		>33
10	>10000	>10000	575±183	>17		>17
11	>10000	>10000	4070±1300	>2		>2
12	4570±1300	>10000	263±86	17		>38
13	>10000	>10000	>10000	1		1
14	711±134	>10000	39±11	18		>256
15	724±137	>10000	427±134	2		>23
16	>10000	>10000	2291±492	>4		>4

N.D. - not determined.

^a see ref. 4, K_i of **2** is 0.6 vs 1.9 nM of **1** for the KOR.

^b Data are mean of three experiments performed in duplicate.

^c The binding affinity constant (K_i) determined against [³H]DAMGO ligand.

^d K_i determined against [³H]DADLE ligand.

^e K_i determined against [³H]U69,553 ligand.

Table 2

Kappa opioid receptor functional assay: Efficacies of $G\alpha_i$ activation in live HEK293 cells using a cAMP biosensor Glosensor-22F (Promega)

Compound	EC ₅₀ ±SD [nM] ^a
1	5±3
4	137±15
5	52±23
7	855±130
14	70±25

^aData are mean of four experiments